Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases

Stefanou,Dimitra; Stamatopoulou,Sofia; Sakellaropoulou,Antigoni; Akakios,Gavriil; Gkiaouraki,Marina; Gkeka,Despina; Prevezanou,Maria; Ardavanis,Alexandros

doi:10.3892/ol.2016.5268

Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases

Authors:
- Dimitra Stefanou
- Sofia Stamatopoulou
- Antigoni Sakellaropoulou
- Gavriil Akakios
- Marina Gkiaouraki
- Despina Gkeka
- Maria Prevezanou
- Alexandros Ardavanis
View Affiliations

Affiliations: First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens 115 22, Greece
Published online on: October 17, 2016 https://doi.org/10.3892/ol.2016.5268
Pages: 4635-4642

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Data concerning bevacizumab plus pemetrexed plus carboplatin as first‑line treatment for patients with non-squamous non-small cell lung cancer (NSCLC) with or without brain metastases (BM) are lacking. The present study analyzed the efficacy and safety of this combination as induction therapy, followed by maintenance therapy with bevacizumab plus pemetrexed in non‑squamous NSCLC patients with or without BM. Treatment‑naïve patients with advanced non‑squamous NSCLC and an Eastern Cooperative Oncology Group performance status score of 0‑2 were eligible. Treatment consisted of carboplatin (area under the curve of 5), pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) every 3 weeks for 6 cycles. Responders and patients with stable disease received maintenance therapy with bevacizumab plus pemetrexed until disease progression, which was evaluated every 3 cycles, or unacceptable toxicity. Kaplan‑Meier median progression‑free survival (PFS) and overall survival (OS) times were the primary endpoints, and safety was the secondary endpoint. In total, 39 patients, aged 44‑78 years (median, 60 years), were treated; 11 (28.2%) of whom presented with BM. The majority of patients (56.4%) completed 6 cycles of induction therapy, and 26 patients continued on to maintenance therapy. The median PFS time was 8.2 months [95% confidence interval (CI), 7.05‑9.35] and the median OS time was 14.0 months (95% CI, 8.46‑19.54). Median PFS and OS times did not differ significantly between patients with or without BM (log rank (Mantel‑Cox): PFS, P=0.748 and OS, P=0.447). The majority of patients (76.9%) did not experience adverse events during treatment. Overall, bevacizumab plus pemetrexed plus carboplatin as induction therapy, followed by bevacizumab plus pemetrexed as maintenance therapy was effective and well tolerated in advanced NSCLC, whether brain metastases were present or not.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Atlas of cancer mortality in the European union and the European Economic Area: 1993–1997. IARC Sci Publ. 1–259. 2008.
3	Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, et al: 2nd ESMO consensus conference on lung cancer: Non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 25:1475–1484. 2014. View Article : Google Scholar : PubMed/NCBI
4	NCCN: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, . Non-Small Cell Lung Cancer. Version I. 2015.https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
5	National Cancer Institute, . PDQ^® Non-Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute; http://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdqAccessed Nov 26, 2014.
6	Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et al: American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
7	Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
9	Schmid-Bindert G: Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC). Target Oncol. 8:15–26. 2013. View Article : Google Scholar : PubMed/NCBI
10	Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT and Bonomi PD: Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 27:3284–3289. 2009. View Article : Google Scholar : PubMed/NCBI
11	Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, et al: Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer. 118:5580–5587. 2012. View Article : Google Scholar : PubMed/NCBI
12	Spigel DR, Hainsworth JD, Shipley DL, Ervin TJ, Kohler PC, Lubiner ET, Peyton JD, Waterhouse DM, Burris HA III and Greco FA: A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol. 7:196–202. 2012. View Article : Google Scholar : PubMed/NCBI
13	Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, et al: PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 31:4349–4357. 2013. View Article : Google Scholar : PubMed/NCBI
14	Yokoi T, Torii Y, Katashiba Y, Sugimoto H, Tanijiri T, Ogata M, Inagaki N, Kibata K, Hayashi M, Niki M, et al: Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer. Oncol Lett. 8:2453–2457. 2014.PubMed/NCBI
15	Malhotra B, Evans T, Weiss J, Eaby B, Stonehouse-Lee S, Sherry V and Langer CJ: Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: A single-institution experience. Clin Lung Cancer. 11:192–197. 2010. View Article : Google Scholar : PubMed/NCBI
16	Nakamura H, Satoh H, Kaburagi T, Nishimura Y, Shinohara Y, Inagaki M, Endo T, Saito T, Hayashihara K, Hizawa N, et al: Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group. Med Oncol. 29:3202–3206. 2012. View Article : Google Scholar : PubMed/NCBI
17	NCCN: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, . Central Nervous System Cancers. Version 2. 2014.https://www.nccn.org/professionals/physician_gls/PDF/cns.pdf
18	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
19	NIH, . Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. simpleevs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
20	Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A and Washington MK: AJCC Cancer Staging Atlas: A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and HandbookAJCC Cancer Staging Atlas: A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and Handbook. 2nd. Springer; New York: 2012, View Article : Google Scholar
21	Parkin DM and Hakulinen T: Cancer registration: Principles and methods. Analysis of survival. IARC Sci Publ. 159–176. 1991.PubMed/NCBI
22	Ali A, Goffin JR, Arnold A and Ellis PM: Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 20:e300–e306. 2013. View Article : Google Scholar : PubMed/NCBI
23	Davis FG, Dolecek TA, McCarthy BJ and Villano JL: Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 14:1171–1177. 2012. View Article : Google Scholar : PubMed/NCBI
24	Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 322:494–500. 1990. View Article : Google Scholar : PubMed/NCBI
25	Louie AV, Rodrigues G, Yaremko B, Yu E, Dar AR, Dingle B, Vincent M, Sanatani M, Younus J, Malthaner R and Inculet R: Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer. 10:174–179. 2009. View Article : Google Scholar : PubMed/NCBI
26	Schuette W: Treatment of brain metastases from lung cancer: Chemotherapy. Lung Cancer. 45:(Suppl 2). S253–S257. 2004. View Article : Google Scholar : PubMed/NCBI
27	Zimmermann S, Dziadziuszko R and Peters S: Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev. 40:716–722. 2014. View Article : Google Scholar : PubMed/NCBI
28	D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F: Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014. View Article : Google Scholar : PubMed/NCBI
29	Bailon O, Chouahnia K, Augier A, Bouillet T, Billot S, Coman I, Ursu R, Belin C, Zelek L, Des Guetz G, et al: Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol. 14:491–495. 2012. View Article : Google Scholar : PubMed/NCBI
30	Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, Bota S, Monnet I, Chajara A and Robinet G: Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: A multicenter phase II trial (GFPC 07–01). Ann Oncol. 22:2466–2470. 2011. View Article : Google Scholar : PubMed/NCBI
31	Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, et al: Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer. 68:264–268. 2010. View Article : Google Scholar : PubMed/NCBI
32	Bernardo G, Cuzzoni Q, Strada MR, Bernardo A, Brunetti G, Jedrychowska I, Pozzi U and Palumbo R: First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study. Cancer Invest. 20:293–302. 2002. View Article : Google Scholar : PubMed/NCBI
33	Edelman MJ, Belani CP, Socinski MA, Ansari RH, Obasaju CK, Chen R, Monberg MJ and Treat J: Alpha Oncology Research Network: Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 5:110–116. 2010. View Article : Google Scholar : PubMed/NCBI
34	Besse B, Lasserre SF, Compton P, Huang J, Augustus S and Rohr UP: Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 16:269–278. 2010. View Article : Google Scholar : PubMed/NCBI
35	Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S and Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 19:843–850. 2001.PubMed/NCBI
36	Morgensztern D and Govindan R: Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: Focus on brain metastasis and squamous histology. Clin Lung Cancer. 9:(Suppl 2). S57–S61. 2008. View Article : Google Scholar : PubMed/NCBI
37	Oh Y and Stewart DJ: Systemic therapy for lung cancer brain metastases: A rationale for clinical trials. Oncology (Williston Park). 22:168–178; discussion 178, 183, 188 passim. 2008.PubMed/NCBI
38	Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L and Akerley W: Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 27:5255–5261. 2009. View Article : Google Scholar : PubMed/NCBI
39	Lynch TJ Jr, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, et al: Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: Final results of the ARIES observational cohort study. J Thorac Oncol. 9:1332–1339. 2014. View Article : Google Scholar : PubMed/NCBI
40	Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL and Zhou C: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): A phase 4 study. Lancet Oncol. 11:733–740. 2010. View Article : Google Scholar : PubMed/NCBI
41	Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI
42	European Medicines Agency, . Committee for Medicinal Products for Human Use Post-Authorisation Summary of Positive Opinion for Avastin. Doc. Ref. No. EMEA/CHMP/121120/2009. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000582/WC500059420.pdf
43	European Medicines Agency, . Assessment Report for Avastin. Doc. Ref. No. EMEA/274499/2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000582/WC500029270.pdf